Skip to main content

Table 3 Overall response rate, PFS, and OS segregated by TMB low/high and PHBR low/high among patients treated with immunotherapy patients (N = 77 with TMB available)

From: MHC-I genotype and tumor mutational burden predict response to immunotherapy

  Rate of SD with ≥ 6 month/PR/CR1 PFS OS
Group N (%) P value Median (months) HR (95% CI) P value2 Median (months) HR (95% CI) P value2
TMB/PHBR (TMB cutoff = 10 mutations/mb)
 Low/high (N = 27) vs. low/low (N = 11) 9 (33%) vs. 2 (18%) 0.45 3.5 vs. 4.2 1.01 (0.48–2.12) 0.99 10.1 vs. 12.0 0.90 (0.37–2.22) 0.82
 Low/high (N = 27) vs. high/high (N = 21) 9 (33%) vs. 9 (43%) 0.56 3.5 vs. 5.8 0.76 (0.54–1.05) 0.09 10.1 vs. 17.2 0.72 (0.47–1.10) 0.12
 Low/high (N = 27) vs. high/low (N = 18) 9 (33%) vs. 14 (78%) 0.006 3.5 vs. 26.8 0.62 (0.47–0.83) < 0.001 10.1 vs. NR3 0.66 (0.47–0.91) 0.008
 Low/low (N = 11) vs. high/high (N = 21) 2 (18%) vs. 9 (43%) 0.25 4.2 vs. 5.8 0.58 (0.25–1.31) 0.18 12.0 vs. 17.2 0.62 (0.23–1.69) 0.34
 Low/low (N = 11) vs. high/low (N = 18) 2 (18%) vs. 14 (78%) 0.003 4.2 vs. 26.8 0.50 (0.30–0.83) 0.003 12.0 vs. NR3 0.59 (0.34–1.02) 0.049
 High/high (N = 21) vs. high/low (N = 18) 9 (43%) vs. 14 (78%) 0.049 5.8 vs. 26.8 0.39 (0.16–0.91) 0.03 17.2 vs. NR3 0.53 (0.19–1.50) 0.23
TMB/PHBR (TMB cutoff = 20 mutations/mb)
 Low/high (N = 38) vs. low/low (N = 18) 13 (34%) vs. 7 (39%) 0.77 4.1 vs. 4.2 0.89 (0.47–1.67) 0.71 11.1 vs. 12.0 0.81 (0.38–1.73) 0.58
 Low/high (N = 38) vs. high/high (N = 10) 13 (34%) vs. 5 (50%) 0.47 4.1 vs. 3.6 0.96 (0.65–1.41) 0.82 11.1 vs. 17.2 0.76 (0.45–1.31) 0.32
 Low/high (N = 38) vs. high/low (N = 11) 13 (34%) vs. 9 (82%) 0.007 4.1 vs. NR4 0.59 (0.41–0.84) 0.001 11.1 vs. NR5 0.66 (0.44–0.99) 0.03
 Low/low (N = 18) vs. high/high (N = 10) 7 (39%) vs. 5 (50%) 0.70 4.2 vs. 3.6 1.06 (0.44–2.53) 0.90 12.0 vs. 17.2 0.82 (0.26–2.62) 0.74
 Low/low (N = 18) vs. high/low (N = 11) 7 (39%) vs. 9 (82%) 0.052 4.2 vs. NR4 0.46 (0.24–0.86) 0.007 12.0 vs. NR5 0.60 (0.31–1.15) 0.11
 High/high (N = 10) vs. high/low (N = 11) 5 (50%) vs. 9 (82%) 0.18 3.6 vs. NR4 0.16 (0.04–0.64) 0.004 17.2 vs. NR5 0.37 (0.08–1.70) 0.19
  1. 1Thirty-six patients achieved SD with ≥ 6 month/PR/CR
  2. 2P values in Fig. 1 are different as they compare all four categories at the same time
  3. 3Not reached to the median (median follow-up duration, 23.0 months)
  4. 4Not reached to the median (median follow-up duration, 24.6 months)
  5. 5Not reached to the median (median follow-up duration, 27.0 months)
  6. Abbreviations: HR hazard ratio, NR not reached to 50%, OS overall survival, PFS progression-free survival, PHBR Patient Harmonic-mean Best Rank, TMB tumor mutational burden